Rheumatology Practice Management Realities
Rheumatology practice management combines longitudinal chronic disease management with substantial biologic infusion revenue. Patient panels build over years — typical rheumatologist manages 1,500-3,000 active chronic patients (RA, lupus, psoriatic arthritis, spondyloarthritis) requiring regular follow-up. Biologic infusion revenue (Remicade, Orencia, Rituxan, Actemra, Benlysta) can represent 25-45% of practice revenue for practices with in-house infusion centers per ACR benchmarks. Medicare patient mix 40-60% typical.
Revenue Cycle Complexity
Revenue cycle complexity comes from biologic infusion workflow and prior authorization intensity. Infusion billing (CPT 96401-96549 series) includes drug cost plus administration fee. Buy-and-bill economics similar to oncology — margin compressed, 340B-eligible practices have advantage. Biologic prior auth extensive — ACR criteria documentation, failure of conventional therapy, specific drug criteria varies by payer. Self-injectable biologics (Humira, Enbrel, Cosentyx) flow through specialty pharmacy rather than practice. Clinical evaluation billing (E/M with joint count, disease activity score documentation) is the smaller revenue line but drives infusion-pipeline volume.
Operational Workflow
Operational workflow spans clinic and infusion center. Clinic: new patient evaluations (2-hour typical slot for comprehensive rheumatologic workup), established patient follow-up with DAS28/CDAI/SDAI scoring, medication management visits. Infusion center: chair scheduling, nursing capacity, pre-medication protocols, drug preparation (in-house compounding or external specialty pharmacy), post-infusion monitoring. Musculoskeletal ultrasound (MSUS) for joint injections, synovitis assessment. Osteoporosis workflow includes DXA scan integration, FRAX assessment, treatment monitoring.
Regulatory & Industry Framework
What Changes at Scale
Scaling rheumatology creates operational leverage around infusion operations. Mid-size groups (3-6 rheumatologists) support in-house infusion center with dedicated RN capacity. Large groups operate multiple infusion centers with consolidated drug purchasing, shared nursing, and platform-wide prior auth operations. PE involvement in rheumatology is emerging — smaller segment than GI or dermatology consolidation but growing given infusion revenue density.
Related Services & Specialties
Geographic Coverage
Practice management support across all 11 NJ counties: Bergen, Hudson, Essex, Passaic, Morris, Union, Middlesex, Monmouth, Somerset, Ocean, Mercer. Major cities: Hackensack, Newark, Jersey City, Paterson, Elizabeth, Morristown, New Brunswick, Princeton, Trenton, Toms River. See complete locations directory.
How an Engagement Starts
Our process is structured, documented, and starts with listening — not pitching.
Step 1 — Discovery call (30 minutes, no obligation). Practice owner or office manager. We listen. What's working, what's broken, what's the immediate pain point. No pitch, no vendor pressure, no slide deck.
Step 2 — Scoped assessment. On-site or remote — we inventory infrastructure, EHR environment, cybersecurity posture, vendor contracts, and clinical workflow patterns. Typically 2-5 business days depending on practice size. Deliverable: a written assessment with findings and prioritized remediation recommendations.
Step 3 — Proposal and engagement structure. If Rheumatology practice management is a fit, we propose an engagement — scope, pricing, timeline, measurable outcomes. No long-term lock-in contracts on first engagement. If we're not the right fit, we'll tell you directly.
Step 4 — Onboarding and delivery. Structured 30-60 day onboarding with clear milestones. Documentation, tooling deployment, knowledge transfer, and operational handoff. You know exactly what's happening and when.
For practices currently with a generalist MSP, see our Qventive vs. generalist MSP comparison. For practices evaluating internal hire vs. managed services, see managed IT vs. internal hire. For questions on the MSP landscape generally, our resources and FAQ pages cover common questions.
Why Qventive, Specifically
Not a pitch — a factual description of how we're structured differently.
Healthcare-exclusive since 1994. Every engineer, every helpdesk technician, every account manager works only with medical practices. No retail, no law firms, no logistics companies. That focus has operational consequences — our on-call engineer at 2 a.m. knows what a downtime toolkit is for Epic. Our helpdesk understands that “the EHR is slow” is an emergency, not a ticket.
Steve Gerbino founded this company in 1994. The founder still answers questions. The depth of specialty and clinical workflow knowledge compounded over three decades is genuinely hard to replicate — and it's why we serve solo practices, group practices, multi-location practices, FQHCs, ASCs, concierge medicine, hospital-adjacent practices, and PE-backed platforms with equal depth.
Observe-Improve-Prevent methodology. Every engagement starts with observation — shadowing providers, auditing infrastructure, reviewing documentation. We don't assume. Then we improve based on what we actually see. Then we monitor continuously to prevent drift. This isn't a marketing slogan — it's an operational pattern baked into how our engineers work.
Geographic proximity. Our Bergen County headquarters in Hackensack means fast on-site response across NJ. We're not a 50-state remote-only MSP. When something needs hands-on work — new infrastructure, physical troubleshooting, device deployment — we send people. Learn more about us, our why Qventive positioning, and read testimonials from practices we serve.
Frequently Asked Questions
Detailed answers from 30+ years of healthcare-exclusive IT and practice management expertise.
How do you handle biologic infusion buy-and-bill?+
Practice purchases biologic at acquisition cost, administers to patient, bills insurance (Medicare Part B: ASP + 6% before sequester; commercial: varies by contract). Margin narrow — drug cost dominates revenue. 340B-eligible practices have substantial cost advantage. Specialty pharmacy alternative (patient gets drug from specialty pharmacy, practice bills administration only) removes drug revenue but also drug acquisition risk and inventory burden.
What about biologic prior auth intensity?+
Essentially universal. Payers require documented diagnosis meeting ACR criteria, failure of conventional DMARDs (methotrexate typically), specific drug criteria (varies by payer — Humira vs. Enbrel vs. Remicade vs. Orencia vs. Cimzia). Authorization work 3-5 hours per new biologic start. Renewal authorizations annually. Denial management substantial.
How do you handle ACR RISE Registry?+
RISE (Rheumatology Informatics System for Effectiveness) is ACR's QCDR for MIPS. Automated data extraction from EHR (most compatible EHRs have RISE integration — ModMed Rheumatology, NextGen Rheumatology). Rheumatology-specific measures. MIPS submission through RISE typically outperforms manual reporting for rheumatology practices.
What about treat-to-target protocols?+
ACR recommends treat-to-target for RA (low disease activity or remission within 6 months) and other rheumatic diseases. DAS28/CDAI/SDAI monitoring at each visit, treatment adjustment based on disease activity. EHR workflow captures disease activity scores, drives treatment decisions, supports quality reporting.
How do you handle osteoporosis workflow?+
DXA scan integration (practice-owned or external), FRAX fracture risk assessment, treatment selection (bisphosphonates, denosumab, romosozumab, teriparatide), ongoing monitoring. Treatment cost (especially romosozumab and teriparatide) and specialty pharmacy integration. Fracture risk documentation for payer authorization.
What about MSUS billing?+
Musculoskeletal ultrasound (CPT 76881/76882 complete/limited) billable when documented for joint injection guidance (CPT 76942) or synovitis assessment. Practice-owned ultrasound and rheumatologist training required. Point-of-care rheumatologic ultrasound is increasingly standard of care for specific indications.
How do you handle new biologic launches?+
Pipeline awareness matters — new biologic launches (new JAK inhibitors, biosimilars, novel mechanism agents) reshape economics. Formulary management, pharmacy partnership negotiation, patient transition workflow, prior auth updates for new drugs. Practice-wide communication when new agents become available.
How does PE change rheumatology PM?+
PE platforms concentrate infusion operations, centralize prior auth, negotiate platform-wide drug contracts, unified reporting across acquired practices. Emerging segment — less mature than GI consolidation but accelerating. See PE page.
Does Qventive serve my area?+
Last Updated: April 2026 · Reviewed by Qventive Healthcare clinical technology team
